Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares saw strong trading volume on Tuesday . 3,653,896 shares traded hands during trading, an increase of 852% from the previous session’s volume of 383,640 shares.The stock last traded at $0.51 and had previously closed at $0.41.

A number of analysts recently issued reports on the stock. ValuEngine downgraded shares of Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. HC Wainwright set a $5.00 target price on shares of Bio-Path Holdings and gave the stock a “buy” rating in a research report on Friday, August 11th. Finally, Zacks Investment Research downgraded shares of Bio-Path Holdings from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.

The stock has a 50 day moving average price of $0.34 and a 200-day moving average price of $0.45. The firm’s market capitalization is $55.93 million.

Bio-Path Holdings (NASDAQ:BPTH) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01). On average, analysts expect that Bio-Path Holdings, Inc. will post ($0.08) earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC purchased a new stake in shares of Bio-Path Holdings during the 1st quarter worth about $105,000. Sabby Management LLC raised its stake in shares of Bio-Path Holdings by 3.5% in the 1st quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock valued at $569,000 after acquiring an additional 23,352 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Bio-Path Holdings by 5,474.3% in the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after acquiring an additional 1,741,978 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Bio-Path Holdings by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after acquiring an additional 5,172 shares in the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Bio-Path Holdings by 9.1% in the 1st quarter. HighTower Advisors LLC now owns 1,263,070 shares of the company’s stock valued at $1,043,000 after acquiring an additional 105,000 shares in the last quarter. 15.16% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Bio-Path Holdings, Inc. (BPTH) Sees Large Volume Increase” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/10/bio-path-holdings-inc-bpth-sees-large-volume-increase.html.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Stock Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related stocks with our FREE daily email newsletter.